Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem and Pralurbactam in HABP/VABP
NCT07327619Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pralubactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Qilu Pharmaceutical. Started Jan 2026; status: recruiting.
02
Drugs
pralubactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07327619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07327619.